- NexImmune Inc NEXI stock is up premarket after the company said that new preclinical data showed that AIM ACT T cells enhance the response to bispecific T cell engager therapy.
- The company said the AIM ACT T cells are non-engineered CTLs against five multiple myeloma antigen-peptide targets and include subtype populations (Tscm, Tcm, Tem) linked with anti-tumor activity and immunologic memory.
- Related: NexImmune Shifts Focus On AIM Direct Injection Platform, Potential Candidates In Oncology & Autoimmune Diseases.
- The abstract describes the ability of multi-TAA AIM ACT T cells to work synergistically with BiTE therapy, showing significant advantages over endogenous TAA nonspecific CD8 T cells + BiTE.
- NexImmune added that the results show that BiTE potency, as measured by a reduction in tumor burden in vivo, is markedly increased in the presence of AIM T cells.
- In addition, after withdrawal of BiTE therapy, recipients of the AIM ACT T cell combination remained tumor-free or had a low tumor burden, while those that had received the bulk CD8+ T cell combination died within two weeks.
- AIM-constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency, and long-term persistence with reduced potential for off-target toxicities.
- Price Action: NEXI shares are up 77.30% at $0.73 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
